Iloprost requires the Frizzled-9 receptor to prevent lung cancer.

ABSTRACT: Prevention of premalignant lesion progression is a promising approach to reducing lung cancer burden in high-risk populations. Substantial preclinical and clinical evidence has demonstrated efficacy of the prostacyclin analogue iloprost for lung cancer chemoprevention. Iloprost activates peroxisome proliferator-activated receptor gamma (PPARG) to initiate chemopreventive signaling and in vitro, which requires the transmembrane receptor Frizzled₉ (FZD₉). We hypothesized a Fzd ₉ ^-/- mouse would not be protected by iloprost in a lung cancer model. Fzd ₉ ^-/- mice were treated with inhaled iloprost in a urethane model of lung adenoma. We found that Fzd ₉

SUBMITTER: Sompel K 

PROVIDER: S-EPMC9189122 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature